Filgrastim Completed Phase 2 Trials for Plasma Cell Neoplasms / Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00028600Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01790737First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
NCT00349778High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
NCT00006184Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
NCT00040937S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00083681DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
NCT00790647Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
NCT01753453An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
NCT02221479Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma